尊龙凯时,尊龙凯时医药集团股份公司官网,尊龙凯时医药集团股份公司,尊龙凯时甾体激素,尊龙凯时麻醉药品

Humanwell Healthcare (Group) Co., Ltd. （Hereafter "Humanwell Healthcare Group"） was founded in 1993, and was listed on the Shanghai Stock Exchange in 1997. The company is the leading enterprise of pharmaceutical industry in Hubei Province, top 30 in the pharmaceutical industry in China, a National Enterprise Technology Center, a national technology innovation demonstration enterprise, and a leading enterprise of the internationalization of pharmaceutical preparations in China. The company has established a leading position in multiple domestic market segments including narcotic drugs, steroid hormones drugs, and Uyghur medicine.

Humanwell adopts the strategy of focusing on the pharmaceutical industry, supplemented by pharmaceutical business, to steadily promote internationalization. For the pharmaceutical industry, the company has achieved the production capacity covering all dosage forms of the whole industry chain composed of pharmaceutical intermediates - raw materials - pharmaceutical excipients - pharmaceutical preparations. For the pharmaceutical business, the company adheres to its position as the "comprehensive provider of medical services", and achieves full coverage of the region through the layout of business network. For internationalization, the company has mastered the entire pharmaceutical value chain, from worldwide R&D and regulatory approval to manufacturing and market promotion; the company has more than 80 products which are exported to more than 70 countries and regions around the world.

The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value; the company aims at the frontiers, to create a first-class innovative research and development industrialization platform. The company has set up research and development centers in Wuhan and Yichang in China, New Jersey and St. Louis in the United States, and Aachen in Germany. The company gathers more than 2,000 pharmaceutical research and development staff, including 9 experts who enjoy the special allowance of The State Council. The company has more than 500 ongoing projects, including more than 60 Class 1、2 new drugs.